Yesterday, a Director at Dermira (DERM), Matthew K. Fust, sold shares of DERM for $52.62K.
This is Fust’s first transaction since reporting a Sell transaction on ATRA back in May 2018 In addition to Matthew K. Fust, one other DERM executive reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Dermira’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $66.65 million and GAAP net loss of $17.96 million. In comparison, last year the company earned revenue of $39.08 million and had a GAAP net loss of $23.93 million. The company has a one-year high of $15.48 and a one-year low of $6.00.
In the last 30 days, insiders have sold $52.62K worth of DERM shares and purchased $200K worth of DERM shares. The insider sentiment on Dermira has been positive according to 23 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dermira, Inc. is a biopharmaceutical company, which engages in the provision of therapies for chronic skin conditions. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis and atopic dermatitis.
